Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal

After a series of blockbuster licensing deals last year, South Korea’s Hanmi has struck another major alliance, this time licensing out a novel oral RAF inhibitor that will strengthen biosimilar-threatened Genentech’s oncology portfolio.